- Home
- MNY vs INKT Comparison
MNY vs INKT Comparison
Compare MNY & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNY
- INKT
- Stock Information
- Founded
- MNY 2014
- INKT 2017
- Country
- MNY Singapore
- INKT United States
- Employees
- MNY N/A
- INKT N/A
- Industry
- MNY
- INKT Medicinal Chemicals and Botanical Products
- Sector
- MNY
- INKT Health Care
- Exchange
- MNY Nasdaq
- INKT Nasdaq
- Market Cap
- MNY 31.9M
- INKT 28.8M
- IPO Year
- MNY N/A
- INKT 2021
- Fundamental
- Price
- MNY $1.53
- INKT $25.38
- Analyst Decision
- MNY Strong Buy
- INKT Hold
- Analyst Count
- MNY 1
- INKT 3
- Target Price
- MNY $4.00
- INKT $37.50
- AVG Volume (30 Days)
- MNY 436.8K
- INKT 2.7M
- Earning Date
- MNY 06-13-2025
- INKT 08-12-2025
- Dividend Yield
- MNY N/A
- INKT N/A
- EPS Growth
- MNY N/A
- INKT N/A
- EPS
- MNY N/A
- INKT N/A
- Revenue
- MNY $71,649,746.00
- INKT N/A
- Revenue This Year
- MNY $16.97
- INKT N/A
- Revenue Next Year
- MNY $19.35
- INKT N/A
- P/E Ratio
- MNY N/A
- INKT N/A
- Revenue Growth
- MNY N/A
- INKT N/A
- 52 Week Low
- MNY $0.55
- INKT $4.56
- 52 Week High
- MNY $1.85
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- MNY 86.96
- INKT 58.01
- Support Level
- MNY $0.99
- INKT $6.80
- Resistance Level
- MNY $1.10
- INKT $76.00
- Average True Range (ATR)
- MNY 0.15
- INKT 6.24
- MACD
- MNY 0.08
- INKT 2.84
- Stochastic Oscillator
- MNY 85.25
- INKT 29.68
About MNY MoneyHero Limited
MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services. Geographically it operates in Singapore, Hong Kong, Taiwan, Malaysia and the Philippines.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.